Teprotumumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06343 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | monosomy X | KG + DL |
| 2 | esophageal varices with bleeding | KG + DL |
| 3 | esophageal varices without bleeding | KG + DL |
| 4 | mixed gonadal dysgenesis | KG + DL |
| 5 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 6 | Turner syndrome due to structural X chromosome anomalies | KG + DL |
| 7 | mosaic monosomy X | KG + DL |
| 8 | sex chromosome disorder of sex development | KG + DL |
| 9 | varicose disease | KG + DL |
| 10 | X chromosome number anomaly | KG + DL |
| 11 | gonadal dysgenesis | KG + DL |
| 12 | Turner syndrome | KG + DL |
| 13 | 46,XY disorder of gonadal development | KG + DL |
| 14 | male infertility due to gonadal dysgenesis | KG + DL |
| 15 | exocrine pancreatic insufficiency | KG + DL |
| 16 | precocious puberty | KG + DL |
| 17 | ichthyosis, X-linked, without steroid sulfatase deficiency | KG + DL |
| 18 | disorder of other vitamins and cofactors metabolism and transport | KG + DL |
| 19 | dappled diaphyseal dysplasia | KG + DL |
| 20 | xanthomatosis (disease) | KG + DL |
| 21 | 46,XY disorder of sexual development due to dihydrotestosterone backdoor pathway biosynthesis defect | KG + DL |
| 22 | chondrodysplasia punctata, brachytelephalangic, autosomal | KG + DL |
| 23 | 46,XY disorder of sex development due to a cholesterol synthesis defect | KG + DL |
| 24 | Astley-Kendall dysplasia | KG + DL |
| 25 | cholesterol catabolic process disease | KG + DL |
| 26 | neutral lipid storage disease | KG + DL |
| 27 | chondrodysplasia punctata, tibial-metacarpal type | KG + DL |
| 28 | Immunoerythromyeloid hypoplasia | KG + DL |
| 29 | spastic paraplegia-optic atrophy-neuropathy and spastic paraplegia-optic atrophy-neuropathy-related disorder | KG + DL |
| 30 | Steel syndrome | KG + DL |
| 31 | 3-hydroxyacyl-CoA dehydrogenase deficiency | KG + DL |
| 32 | non-severe combined immunodeficiency | KG + DL |
| 33 | hypophosphatasia | KG + DL |
| 34 | pulmonary arterial hypertension associated with congenital heart disease | KG + DL |
| 35 | lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome | KG + DL |
| 36 | pulmonary arterial hypertension associated with HIV infection | KG + DL |
| 37 | pulmonary arterial hypertension associated with schistosomiasis | KG + DL |
| 38 | pulmonary arterial hypertension associated with connective tissue disease | KG + DL |
| 39 | pulmonary arterial hypertension associated with chronic hemolytic anemia | KG + DL |
| 40 | T-B+ severe combined immunodeficiency due to CD45 deficiency | KG + DL |
| 41 | spastic paraplegia | KG + DL |
| 42 | syndromic dyslipidemia | KG + DL |
| 43 | Ambras type hypertrichosis universalis congenita | KG + DL |
| 44 | malformation syndrome with odontal and/or periodontal component | KG + DL |
| 45 | pulmonary arteriovenous malformation (disease) | KG + DL |
| 46 | T-B+ severe combined immunodeficiency due to gamma chain deficiency | KG + DL |
| 47 | pulmonary arterial hypertension | KG + DL |
| 48 | squamous cell lung carcinoma | KG + DL |
| 49 | ACTH-dependent Cushing syndrome | KG + DL |
| 50 | isolated genetic hair shaft abnormality | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.